DK1054064T3 - Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35 - Google Patents
Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35Info
- Publication number
- DK1054064T3 DK1054064T3 DK00201738T DK00201738T DK1054064T3 DK 1054064 T3 DK1054064 T3 DK 1054064T3 DK 00201738 T DK00201738 T DK 00201738T DK 00201738 T DK00201738 T DK 00201738T DK 1054064 T3 DK1054064 T3 DK 1054064T3
- Authority
- DK
- Denmark
- Prior art keywords
- adenovirus
- serotypes
- tropism
- proteins
- vehicles
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 6
- 238000001476 gene delivery Methods 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 3
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 3
- 230000010415 tropism Effects 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101710145505 Fiber protein Proteins 0.000 abstract 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99201545 | 1999-05-17 | ||
PCT/NL2000/000325 WO2000070071A1 (en) | 1999-05-17 | 2000-05-16 | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1054064T3 true DK1054064T3 (da) | 2005-01-10 |
DK1054064T4 DK1054064T4 (da) | 2010-05-03 |
Family
ID=8240209
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07106036.2T DK1818408T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af serotypen Ad11 |
DK00201738.2T DK1054064T4 (da) | 1999-05-17 | 2000-05-16 | Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35 |
DK07106044.6T DK1816204T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af Ad26-serotypen |
DK07106054.5T DK1816205T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus på grundlag af serotypen Ad48 |
DK04077434T DK1550722T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant human adenovirus serotype 35 |
DK05077719T DK1681353T3 (da) | 1999-05-17 | 2000-05-16 | Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07106036.2T DK1818408T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af serotypen Ad11 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07106044.6T DK1816204T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus af Ad26-serotypen |
DK07106054.5T DK1816205T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant adenovirus på grundlag af serotypen Ad48 |
DK04077434T DK1550722T3 (da) | 1999-05-17 | 2000-05-16 | Rekombinant human adenovirus serotype 35 |
DK05077719T DK1681353T3 (da) | 1999-05-17 | 2000-05-16 | Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 |
Country Status (14)
Country | Link |
---|---|
EP (6) | EP1818408B1 (da) |
JP (2) | JP4843145B2 (da) |
KR (1) | KR100741247B1 (da) |
AT (6) | ATE485382T1 (da) |
AU (1) | AU777041B2 (da) |
CA (1) | CA2372655C (da) |
CY (4) | CY1106762T1 (da) |
DE (4) | DE60035229T2 (da) |
DK (6) | DK1818408T3 (da) |
ES (5) | ES2372823T3 (da) |
IL (3) | IL146479A0 (da) |
NZ (1) | NZ515582A (da) |
PT (5) | PT1818408E (da) |
WO (1) | WO2000070071A1 (da) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1445322E (pt) | 1995-06-15 | 2010-01-19 | Crucell Holland Bv | Sistemas de empacotamento para adenovírus recombinante humano destinados a terapia genética |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7094398B1 (en) | 1999-06-01 | 2006-08-22 | University Of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
EP1191105A1 (en) * | 2000-09-25 | 2002-03-27 | Galapagos Genomics B.V. | Gene delivery vectors provided with a tissue tropism for T-lymphocytes |
AU2001263689B2 (en) | 2000-05-31 | 2007-03-22 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
EP1322774A2 (en) * | 2000-09-20 | 2003-07-02 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for dendritic cells |
DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
EP1195440A1 (en) * | 2000-10-06 | 2002-04-10 | Introgene B.V. | Gene delivery vectors for stem cells |
AU2002211087A1 (en) * | 2000-10-06 | 2002-04-15 | Crucell Holland B.V. | Gene delivery vectors for stem cells |
AU2002217721A1 (en) * | 2001-01-04 | 2002-07-16 | Kristina Lindman | Viral vector for gene therapy |
WO2002068627A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
WO2003062400A2 (en) * | 2002-01-24 | 2003-07-31 | The Scripps Research Institute | Fiber shaft modifications for efficient targeting |
NZ534865A (en) * | 2002-04-25 | 2008-07-31 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
DE60329835D1 (de) | 2002-04-25 | 2009-12-10 | Crucell Holland Bv | Mittel und verfahren zur herstellung von adenovirusvektoren |
JP4237449B2 (ja) * | 2002-06-05 | 2009-03-11 | 国立医薬品食品衛生研究所長 | アデノウィルスベクター |
US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
US20050036989A1 (en) * | 2003-07-18 | 2005-02-17 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
ES2329607T3 (es) | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
EP1737885A2 (en) * | 2004-04-12 | 2007-01-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
KR101169109B1 (ko) | 2004-05-26 | 2012-07-26 | 싸이오서스 테라퓨틱스 엘티디. | 암 치료에 사용하기 위한 키메릭 아데노바이러스 |
MX2007004188A (es) | 2004-10-13 | 2007-10-11 | Crucell Holland Bv | Vectores adenovirales mejorados y usos de los mismos. |
KR101255870B1 (ko) | 2004-11-16 | 2013-04-17 | 아에라스 글로벌 티비 백신 파운데이션 | 재조합 바이러스 벡터를 포함하는 다가 백신 |
DK1869171T4 (da) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virusrensning under anvendelse af ultrafiltrering |
EP1907536B1 (en) | 2005-07-22 | 2010-04-07 | Crucell Holland B.V. | Cell line for producing coronaviruses |
US20100143302A1 (en) * | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
ES2532015T3 (es) | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
KR20120052352A (ko) | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Hbv 감염을 치료하는 조성물 |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
US20120315696A1 (en) * | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
NZ628385A (en) | 2012-03-12 | 2016-09-30 | Crucell Holland Bv | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
AP2014007994A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against rsv |
US9476061B2 (en) | 2012-05-24 | 2016-10-25 | Janssen Vaccines & Prevention B.V. | Adenoviral vectors for transduction of vascular tissue |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
MX366206B (es) | 2012-07-10 | 2019-07-02 | Transgene Sa | Vacuna de antígeno micobacteriano. |
SG11201503864TA (en) | 2012-11-16 | 2015-06-29 | Beth Israel Hospital | Recombinant adenoviruses and use thereof |
CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
CN110590916A (zh) | 2013-04-25 | 2019-12-20 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
CA2927968C (en) | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
US10765731B2 (en) | 2014-01-09 | 2020-09-08 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
SG11201701745TA (en) | 2014-09-03 | 2017-04-27 | Bavarian Nordic As | Methods and compositions for enhancing immune responses |
PT3656395T (pt) | 2014-09-03 | 2024-02-09 | Bavarian Nordic As | Métodos e composições para induzir imunidade protetora contra infeção por filovírus |
SG11201702110RA (en) | 2014-09-26 | 2017-04-27 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
CN107075521B (zh) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
SI3288573T1 (sl) | 2015-04-30 | 2020-06-30 | Psioxus Therapeutics Limited | Onkolitični adenovirus, ki kodira protein B7 |
EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
IL288541B (en) | 2015-07-07 | 2022-08-01 | Janssen Vaccines Prevention B V | vaccine against rsv |
MY195389A (en) | 2015-08-20 | 2023-01-18 | Janssen Vaccines & Prevention Bv | Therapeutic HPV18 Vaccines |
SI3390430T1 (sl) | 2015-12-15 | 2019-12-31 | Janssen Vaccines & Prevention B.V. | Antigeni virusa humane imunske pomanjkljivosti, vektorji, sestavki in postopki njihove uporabe |
AU2016369485B2 (en) | 2015-12-17 | 2024-02-01 | Akamis Bio Limited | Group B adenovirus encoding an anti-TCR-complex antibody or fragment |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
KR102401247B1 (ko) | 2016-04-05 | 2022-05-25 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
MY190320A (en) | 2016-04-05 | 2022-04-13 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
US10517944B2 (en) | 2016-05-02 | 2019-12-31 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV vaccine combinations |
EA039124B1 (ru) | 2016-05-30 | 2021-12-08 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные f-белки rsv до слияния |
CN109219448B (zh) | 2016-06-16 | 2022-09-20 | 扬森疫苗与预防公司 | Hiv疫苗配制品 |
CN109312362B (zh) | 2016-06-20 | 2022-06-28 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hpvワクチン |
WO2018011768A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines And Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
US10925955B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a Marburg virus infection |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
NZ755252A (en) | 2017-02-09 | 2022-05-27 | Janssen Vaccines & Prevention Bv | Potent and short promoter for expression of heterologous genes |
US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
CA3066573A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
CN111163800A (zh) | 2017-09-15 | 2020-05-15 | 扬森疫苗与预防公司 | 用于安全诱导针对rsv的免疫的方法 |
WO2019099970A1 (en) | 2017-11-20 | 2019-05-23 | Janssen Pharmaceuticals Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
EP3723771A4 (en) | 2017-12-11 | 2022-04-06 | Beth Israel Deaconess Medical Center, Inc. | RECOMBINANT ADENOVIRUS AND THEIR USES |
CN111741766A (zh) | 2017-12-19 | 2020-10-02 | 杨森科学爱尔兰无限公司 | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 |
US11713469B2 (en) | 2018-07-20 | 2023-08-01 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing Zika antigen with improved productivity |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
JP2022532723A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与 |
JP2022532742A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置 |
CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
CN111337042B (zh) * | 2020-03-13 | 2021-11-02 | 湖北大学 | 一种车辆路径规划方法及系统 |
WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
TW202216190A (zh) | 2020-07-08 | 2022-05-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 抗hbv之rna複製子疫苗 |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
IL301955A (en) | 2020-10-07 | 2023-06-01 | Asklepios Biopharmaceutical Inc | Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21 |
EP4267605A2 (en) | 2020-12-23 | 2023-11-01 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725726B1 (fr) * | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
PT1445322E (pt) | 1995-06-15 | 2010-01-19 | Crucell Holland Bv | Sistemas de empacotamento para adenovírus recombinante humano destinados a terapia genética |
US5837511A (en) * | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US6100086A (en) * | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
AU776067B2 (en) * | 1999-03-04 | 2004-08-26 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
JP2011521985A (ja) * | 2008-06-03 | 2011-07-28 | オカイロス アーゲー | Hcv感染の予防および治療のためのワクチン |
-
2000
- 2000-05-16 ES ES07106036T patent/ES2372823T3/es not_active Expired - Lifetime
- 2000-05-16 AU AU49547/00A patent/AU777041B2/en not_active Expired
- 2000-05-16 AT AT07106044T patent/ATE485382T1/de active
- 2000-05-16 DK DK07106036.2T patent/DK1818408T3/da active
- 2000-05-16 IL IL14647988A patent/IL146479A0/xx unknown
- 2000-05-16 DE DE60035229T patent/DE60035229T2/de not_active Expired - Lifetime
- 2000-05-16 WO PCT/NL2000/000325 patent/WO2000070071A1/en active Application Filing
- 2000-05-16 PT PT07106036T patent/PT1818408E/pt unknown
- 2000-05-16 PT PT07106044T patent/PT1816204E/pt unknown
- 2000-05-16 EP EP07106036A patent/EP1818408B1/en not_active Expired - Lifetime
- 2000-05-16 ES ES07106054T patent/ES2372824T3/es not_active Expired - Lifetime
- 2000-05-16 ES ES04077434T patent/ES2289426T3/es not_active Expired - Lifetime
- 2000-05-16 DK DK00201738.2T patent/DK1054064T4/da active
- 2000-05-16 PT PT07106054T patent/PT1816205E/pt unknown
- 2000-05-16 ES ES00201738T patent/ES2231103T5/es not_active Expired - Lifetime
- 2000-05-16 AT AT07106036T patent/ATE519855T1/de active
- 2000-05-16 EP EP00201738A patent/EP1054064B2/en not_active Expired - Lifetime
- 2000-05-16 DE DE60043126T patent/DE60043126D1/de not_active Expired - Lifetime
- 2000-05-16 AT AT07106054T patent/ATE519854T1/de active
- 2000-05-16 AT AT04077434T patent/ATE364707T1/de active
- 2000-05-16 DK DK07106044.6T patent/DK1816204T3/da active
- 2000-05-16 NZ NZ515582A patent/NZ515582A/en not_active IP Right Cessation
- 2000-05-16 JP JP2000618477A patent/JP4843145B2/ja not_active Expired - Lifetime
- 2000-05-16 PT PT00201738T patent/PT1054064E/pt unknown
- 2000-05-16 AT AT00201738T patent/ATE278792T1/de active
- 2000-05-16 AT AT05077719T patent/ATE445018T1/de not_active IP Right Cessation
- 2000-05-16 EP EP05077719A patent/EP1681353B1/en not_active Expired - Lifetime
- 2000-05-16 ES ES07106044T patent/ES2354578T3/es not_active Expired - Lifetime
- 2000-05-16 DE DE60045138T patent/DE60045138D1/de not_active Expired - Lifetime
- 2000-05-16 DK DK07106054.5T patent/DK1816205T3/da active
- 2000-05-16 EP EP07106054A patent/EP1816205B1/en not_active Expired - Lifetime
- 2000-05-16 DE DE60014489T patent/DE60014489T3/de not_active Expired - Lifetime
- 2000-05-16 DK DK04077434T patent/DK1550722T3/da active
- 2000-05-16 EP EP04077434A patent/EP1550722B1/en not_active Expired - Lifetime
- 2000-05-16 PT PT04077434T patent/PT1550722E/pt unknown
- 2000-05-16 CA CA2372655A patent/CA2372655C/en not_active Expired - Lifetime
- 2000-05-16 KR KR1020017014631A patent/KR100741247B1/ko active IP Right Grant
- 2000-05-16 EP EP07106044A patent/EP1816204B1/en not_active Expired - Lifetime
- 2000-05-16 DK DK05077719T patent/DK1681353T3/da active
-
2001
- 2001-11-13 IL IL146479A patent/IL146479A/en not_active IP Right Cessation
-
2007
- 2007-07-25 CY CY20071100996T patent/CY1106762T1/el unknown
-
2011
- 2011-01-10 CY CY20111100030T patent/CY1111494T1/el unknown
- 2011-07-14 JP JP2011156125A patent/JP5335037B2/ja not_active Expired - Lifetime
- 2011-08-02 IL IL214413A patent/IL214413A/en not_active IP Right Cessation
- 2011-11-07 CY CY20111101074T patent/CY1112008T1/el unknown
- 2011-11-07 CY CY20111101075T patent/CY1112189T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1054064T3 (da) | Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35 | |
ATE237694T1 (de) | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt | |
JP2002537816A5 (da) | ||
WO2002018948A3 (en) | Differentially expressed epitopes and uses thereof | |
EP1731612A4 (en) | RECOMBINANT HERPESVIRUS AND ITS USE | |
WO2006086357A3 (en) | Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby | |
WO2003099859A3 (de) | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren | |
EP1270586A3 (de) | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen | |
AU2002228805A1 (en) | Antisense modulation of damage-specific dna binding protein 2, p48 expression | |
NO20005081D0 (no) | Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav | |
FR2799472B1 (fr) | Preparation d'adenovirus recombinants et de banques adenovirales | |
AU2001284511A1 (en) | Impartment of virus-resistance with the use of plant protein binding to plant virus transport protein | |
WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
WO2002083902A3 (en) | Adenovirus serotype 30 (ad30) fiber protein and uses thereof | |
WO2002081514A3 (en) | A novel f-box protein | |
坂口実 | TWO-PERSON HI-LO POKER: STUD AND DRAW, II | |
WO2001077293A3 (en) | Gp40 and uses thereof | |
WO2001079498A3 (en) | 16051a and 16051b, novel human pdz family members and uses thereof | |
Strauss et al. | Orchestral works | |
Mohlenbrock | Leaf Reading in Oahu. | |
Asgharian et al. | A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q] | |
ZA987310B (en) | Interleukin-18 binding proteins, their preparation and use. | |
DK1015595T3 (da) | Peptider afledt fra bindings (G)-proteinet fra respiratorisk syncytialvirus | |
AU2003200442A1 (en) | Interleukin-18 binding proteins, their preparation and use |